Bimin W. Shi
188 Shizi Street
Suzhou, China
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.
Journal: Diabetologia
Published: March 19, 2026
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: January 22, 2026
Targeting GHSR-1α with silibinin to enhance mitophagy and prevent tubular injury in diabetic kidney disease.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: January 16, 2026
Association Between Pancreatic β-Cell Function and Quantitative OCT Angiography Metrics in Patients with Type 2 Diabetes Without Clinical Diabetic Retinopathy.
Journal: Current eye research
Published: January 12, 2026
Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.
Journal: Advances in therapy
Published: September 29, 2025
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.
Journal: Diabetes, obesity & metabolism
Published: September 15, 2025
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
Journal: Contemporary clinical trials
Published: June 26, 2025
Mazdutide versus placebo in Chinese adults with type 2 diabetes.
Journal: Nature
Published: June 16, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.
Journal: Diabetologia
Published: May 01, 2025
A panel of serum-derived exosomal miRNAs as markers of cardiovascular risk assessed by carotid intima-media thickness in patients with type 2 diabetes.
Journal: American journal of translational research
Published: April 16, 2025
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Nature communications
Published: March 31, 2025
Last Updated: 09/26/2026